| Date | Title | Description |
| 22.04.2026 | STORM Therapeutics Secures $56 Million, Advances Novel Sarcoma Therapy to Phase 2 | STORM Therapeutics, a clinical-stage biotechnology firm, secured $56 million in Series C financing. This significant capital infusion will drive the advancement of STC-15, its groundbreaking first-in-class METTL3 inhibitor. STC-15 has now e... |
| 20.04.2026 | STORM Therapeutics secures $56 million series C financing and doses first patient in phase 2 Sarcoma Trial of STC‑15 | The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications
First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation
16 April 2026, Cambridge, UK: STORM Th... |
| 16.04.2026 | STORM Therapeutics Raises $56M in Series C Funding | STORM Therapeutics, a Cambridge, UK-based, clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, raised $56M in Series C funding.
Backers included M Ventures, Pfizer Ventures, Taiho Ventur... |
| 16.04.2026 | Storm Therapeutics Secures $56M to Advance Cancer Drugs | Storm Therapeutics has recently completed a $56M Series C financing round, an indicator of a new era for the treatment of a number of rare and aggressive cancers. As announced on April 16, 2026, the proceeds will be used to initiate Phase 2... |
| 13.02.2026 | AMPLY Discovery Receives Investment from Keeps Biomed | Dermot Tierney (AMPLY, COO), Ben Thomas (AMPLY, CEO), Oliver Rausch (AMPLY, CSO)
AMPLY Discovery, a Belfast, Northern Ireland, UK-based developer of an AI-driven drug discovery platform, received a strategic investment from Keeps Biomed, a ... |
| 19.12.2022 | STORM Therapeutics announces closing of USD $30M Series B financing. | 14 December, 2022. Cambridge, England. STORM Therapeutics Ltd. (STORM), the clinical biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, tod... |
| 14.12.2022 | STORM Therapeutics Ltd - STORM Therapeutics announces closing of USD $30M Series B financing |
STORM Therapeutics announces closing of USD $30M Series B financing
Proceeds will advance STORM’s potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias
Financing will further expand... |
| 14.12.2022 | Storm Therapeutics Closes USD $30M Series B Financing | Storm Therapeutics, a Cambridge, UK-based clinical biotechnology company, raised $30M in Series B financing.
The round was co-led by M Ventures, and Pfizer Ventures, with participation from Taiho Ventures LLC, Cambridge Innovation Capital, ... |
| 14.12.2022 | STORM Therapeutics announces closing of USD $30M Series B financing | STORM Therapeutics announces closing of USD $30M Series B financing
Proceeds will advance STORM’s potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias
Financing will further expand STORM’s n... |
| 23.11.2022 | STORM Therapeutics doses first patient with oral METTL3 targeting drug in a solid tumor Phase 1 study | STORM Therapeutics doses first patient with oral METTL3 targeting drug in a solid tumor Phase 1 study
STC-15 is the first molecule specifically targeting an RNA methyltransferase to enter clinical development
STORM Therapeutics Ltd. (STORM)... |
| 23.11.2022 | STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study | STC-15 is the first molecule specifically targeting an RNA methyltransferase to enter clinical development
CAMBRIDGE, England, Nov. 23, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developi... |
| 20.10.2022 | STORM Therapeutics to present new data on its lead program STC-15 | STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting
STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule ther... |
| 12.09.2022 | Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022 | Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022
STORM recognised as an innovative early-stage biotechnology company pioneering novel drug targets
STORM Therapeutics Ltd. (STORM), the biotechnology... |
| 04.05.2022 | STORM Therapeutics funded to fight coronavirus diseases | STORM Therapeutics funded to fight coronavirus diseases
Business Weekly article | By Tony Quested
Cambridge University spin-out STORM Therapeutics has won an unspecified Biomedical Catalyst grant by Innovate UK to research and develop new d... |
| 14.10.2021 | Exelixis and STORM enter into exclusive collaboration to discover and develop inhibitors of novel RNA modifying enzymes | Exelixis and STORM Therapeutics enter into exclusive collaboration and license agreement to discover and develop inhibitors of novel RNA modifying enzymes
Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that the... |
| 26.04.2021 | STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML | STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML
Expected to be first RNA epigenetic drug programme globally to enter the clinic in 2022
STORM ... |
| 30.12.2020 | Storm Therapeutics announces publication of “RNA-Modifying Enzymes and their Inhibitors” | Storm Therapeutics announces publication of “RNA-Modifying Enzymes and their Inhibitors” in 2020 Medicinal Chemistry Reviews Publication provides timely and critical reviews of important topics in medicinal chemistry
STORM Therapeutics, the... |
| 22.10.2020 | Storm Therapeutics selects first-in-class clinical candidate targeting METTL3 | STORM Therapeutics selects first-in-class clinical candidate targeting METTL3
STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, today annou... |
| 20.05.2019 | Storm Therapeutics Raises Additional £14M in Series A Totalling £30M | Storm Therapeutics, a Cambridge, England, UK-based drug discovery company tackling disease through modulating RNA modifying enzymes, raised an additional £14m bringing the total Series A financing to £30m.
The financing included funding fro... |
| 20.05.2019 | STORM Therapeutics - STORM Therapeutics Extends Series A to £30m (USD 38.43m) with New Investor, Seroba Life Sciences |
STORM Therapeutics ("STORM"), the drug discovery company tackling disease through modulating RNA modifying enzymes, today announced that it has raised an additional £14 million bringing the total Series A financing to £30 millio... |
| 09.01.2018 | Term Sheet — Tuesday, January 9 | A DYNAMITE YEAR
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
The U.S. venture capital industry deployed $84 billion invested in 8,035 companies across 8,076 deals, according to a new Pitch... |
| 09.01.2018 | Storm Therapeutics Raises £4M in Series A Funding | Storm Therapeutics, a Cambridge, MA-based drug discovery company focused on small molecule therapies modulating RNA modifying enzymes, raised an additional £4m of funding.
Taiho Ventures, LLC, the strategic corporate venture capital arm of ... |
| 08.01.2018 | Taiho invests in STORM Therapeutics | STORM Therapeutics has raised an additional £4 million of funding from Taiho Ventures, LLC the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd. This is an addition to the £12 million Series A Financing announced in ... |
| 27.11.2017 | Nature publication on RNA epigenetics by STORM Therapeutics founder Professor Tony Kouzarides | New drug target discovered for Acute Myeloid Leukaemia
STORM Therapeutics announced the publication of data in the internationally renowned scientific journal Nature linking an essential RNA-modifying enzyme to acute myeloid leukaemia (AML)... |
| 06.11.2017 | Professor Paul Workman joins the board of STORM Therapeutics | STORM Therapeutics has announced the appointment of Professor Paul Workman to its Board. This appointment continues STORM’s evolution of its management and advisory networks as it fulfils its ambition to become the leading therapeutics comp... |
| 28.07.2017 | Cambridge spin-out STORM Therapeutics expands collaboration with Evotec | Evotec AG announced an integrated drug discovery collaboration with STORM Therapeutics to develop new small molecule epigenetic drugs for oncology and other therapeutic areas. The focus will be on a range of newly discovered RNA modulating ... |
| 28.07.2017 | Cambridge spin-out STORM Therapeutics expands collaboration with Evotec | Cambridge spin-out STORM Therapeutics expands collaboration with Evotec
28-07-2017
Evotec AG announced an integrated drug discovery collaboration with STORM Therapeutics to develop new small molecule epigenetic drugs for oncology and other ... |
| 29.03.2017 | Postscript designs a new website for RNA epigenetics pioneer STORM Therapeutics | Postscript designs a new website for RNA epigenetics pioneer STORM Therapeutics
29-03-2017
Web design and marketing agency Postscript has designed and built the new website for Babraham Research Campus based STORM Therapeutics, an emerging ... |
| 24.02.2017 | Storm Therapeutics appoints CEO and Chairman | Storm Therapeutics moved to the next stage of its development with the appointment of Keith Blundy as Chief Executive Officer and Tim Edwards as Chairman.
Keith, formerly CEO of Cancer Research Technology, brings his extensive knowledge of ... |
| 28.06.2016 | Storm Therapeutics raises £12m in Series 'A' funding | Storm Therapeutics raises £12m in Series 'A' funding
28-06-2016
Cambridge Innovation Capital has invested in the Series ‘A’ funding round of Storm Therapeutics (formerly known as Iceni Therapeutics), a spin-out company from the University o... |
| 28.06.2016 | Cancer Drug Development Company Storm Therapeutics Raises £12M | Storm Therapeutics, a Cambridge, UK-based cancer drug development company, secured £12m in Series A funding.
Backers included Imperial Innovations, Cambridge Innovation Capital, Merck Ventures and Pfizer Venture Investments.
The company wil... |
| - | STORM Therapeutics selects first-in-class clinical candidate targeting METTL3 | Cambridge, UK. 22 October 2020. Seroba’s investee company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has announced that STC-15, its... |
| - | FutureNeuro partners with STORM Therapeutics to explore the role of RNA epigenetics in epilepsy. | Dublin, Ireland. 9 September 2020. FutureNeuro has announced that it has entered into partnership with Seroba’s portfolio company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molec... |
| - | Storm Therapeutics | “STORM Therapeutics is a pioneer in the field of RNA epigenetics. We are an emerging biotechnology company in Cambridge, UK, focused on developing small molecule inhibitors of RNA-modifying enzymes for the treatment of cancer.” |
| - | Storm Therapeutics and Evotec Leverage Indigo Platform to Progress Oncology Project. | Hamburg, Germany. 17 November 2020. Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that, as part of its ongoing collaboration with STORM Therapeutics (“STORM”), the leading biotechnology company f... |
| - | Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes. | California, USA and Cambridge, UK. 14 October 2021.
STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform.
Exelixis, Inc. (Nasdaq: EXEL) and STORM ... |
